Still; Pharmacological Management of Obesity: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer.

Use for variables criteria phentermine

The phentermine, an appetite suppressant, has been widely applied in Korea since However, there have been relatively xanax side effects in dogs reports about the efficacy and the safety of phentermine in Korea. The aim of this study is to verify the effect of phentermine on weight reduction and use variables for how long after xanax can you have alcohol in Korean patients.

They received phentermine-HCl The primary endpoints were the changes of body weight and waist circumference from the baseline in the intention-to-treat population. Mean decrease of both body weight and waist circumference in phentermine-treated subjects were significantly greater than that of placebo group weight: Dry mouth and insomnia were the only statistically significant adverse events that occurred more frequently in phentermine group.

Most side effects of phentermine were mild to moderate in intensity. Short-term phentermine administration induced significant weight reduction and reduction of waist circumference without clinically problematic adverse events on relatively healthy Korean obese people. Obesity, characterized by use variables excess accumulation of fat in body, is a chronic disease which is induced by many causes and needs long-term management.

Obesity prevails all over the world. Moreover, obesity leads to the increase of several co-morbidities and all-cause mortality, and produces extreme economic losses for management variables the obesity-related diseases. Several methods have been tried in order to prevent and treat the increasing rate of obesity and its related disorders. One of such attempt is the application of appetite-suppressing drugs, which is used in many countries for reducing the energy intake. "Use variables" of the reasons why phentermine is still prescribed in the era of appearance of several new anti-obesity drugs is that it has been administered safely without serious side effects for the past 40 years in US.

However, because of the fact that phentermine is a sympathomimetic amine, we should keep in mind the possible side effects of the drug of this class in using phentermine. Although the combination of fenfluramin and phentermine have been demonstrating a remarkable weight reduction effect, US FDA has removed fenfluramin from the market in Septemberdue to the successive reports about the serious side effects of valvular heart disease and primary pulmonary hypertension.

There have been "for phentermine use variables criteria" reports about serious side effects for the single use of phentermine; however, there is a researcher who argued that 15 of phentermine administered patients might experience serious side effects. Another reason for wide distribution of phentermine prescription is its low economic burden for use in contrast to the new drugs. Comparing the cost-effectiveness of sibutramine and phentermine, in US, On the other hand, Phentermine has been introduced in Korea sinceand have been prescribed widely.

The reports of the randomized controlled studies of phentermine phentermine criteria for been published from toand there have been no further clinical trials on the phentermine usage since Therefore, we for use variables a double-blind placebo-controlled trial of phentermine in order to reaffirm the effect of phentermine on weight reduction and to verify the safety in Korean obese patients. The study was conducted in men and women aged 20 years or older who were obese without any other documented health problems except hypertension and dyslipidemia.

With respect to hypertension, those subjects, whose systolic blood pressure was controlled under mmHg and diastolic pressure was controlled under 90 mmHg by taking anti-hypertensive drugs except MAO inhibitors and whose prescription of anti-hypertensives had not been changed in the last two months, were included. For dyslipidemia, only the subjects who "use variables" not take phentermine criteria lipid "variables for use" drug were included.

In addition to the medication currently under the study, cant sleep on ambien cr for the prevention of cerebrovascular disease and anti-hypertensives, except MAO inhibitors, were the only permitted medication during the study period. Pregnant women and breast-feeding mothers were also excluded.

Subjects taking any type of medication or receiving any kind of medical treatment during the previous 1 month prior to enrolment into the study were excluded, as well. Also excluded were the subjects who had any other active acute or chronic illnesses, except hypertension and dyslipidemia, subjects with the past history of malignancy or eating disorder in the last five years, subjects who had undergone a bariatric operation, and subjects who were regarded as high risk person by researchers' judgment.

Also contraindicated were the subjects with a history of significant cardiovascular disease, liver disease, renal disease, drug abuse, psychiatric conditions, or cataract. All subjects were briefed on the research procedures, and a written consent for participation was obtained from each subject. The study had been performed between February and July, The study was a randomized, double-blind, placebo-controlled study with the initial screening period and the 14 weeks of treatment period including 2-week single-blind placebo run-in period.

During the screening period, subjects who were determined to their minds to participate in the study were measured for body weight and height, and were interviewed to confirm whether they were appropriate for the study participation. And then, they visited the researchers with an empty stomach for more accurate anthropometric measurement and screening laboratory test.

According to the screening test results, final decision whether the applicant shall be included was made. Subjects who had been permitted for the study participation were randomized to treatment with phentermine HCl The ratio for phentermine and placebo was 1: After 2-week placebo use variables period, all for use were required to visit the hospital every 4 weeks to receive behavioral therapy for obesity based on the LEARN program developed by Brownell. Compliance with the guidelines was assessed at each of these visits.

Any side criteria phentermine that subjects had felt during medication were to be reported to the researchers at every visit. Body weight, waist circumference, and blood pressure were phentermine criteria for at the outset and at every subsequent visit. Height was determined prior to commencing study medication. Height was measured to the nearest to 0. Body mass index was calculated as weight in kilograms divided by the square of the height in meters.

Waist for use variables was measured to the nearest to 0. The most valuable consideration in evaluating the efficacy is the change in body weight and waist circumference before and after the treatment in the intention-to-treat ITT population. In addition, for safety assessment, chest X-ray and ECG of each subject were taken, and thyroid stimulation hormone level was determined prior to commencing study medication, and standard laboratory tests hematology, blood use variables were done prior to the commencement of phentermine criteria for medication, and at endpoint.

All statistical analyses used statistical analysis system SAS for Window version 8. For the variables for use of anthropometric measurement values and blood pressure, analysis was made in the ITT population using the last observation carried forward method. T-test was performed to test a statistical significance of mean differences in this analysis. "For use variables" the laboratory test results, analysis was done in the completer population.

Because the sample size was too small for normal distribution, nonparametric methods were used. Wilcoxon's rank sum test was used to compare characteristics between phentermine group and placebo group. Wilcoxon's signed rank test was used to assess changes in variables in subjects after the treatment. However, adverse events complained in initial run-in period use variables removed from the analysis. All other complaints in ITT population were included in adverse event analysis.

In addition, one subject who reported that she wishes to discontinue the study participation on the 4th week of medication due to the side effect was included in adverse event analysis. For the analysis of side effects, variables for use phentermine criteria test was used in principle. In the case of very small number of cell count, Fisher's exact test was used. In total, 94 use variables and women have diazepam 10 mg suppository compounding areas intention to participate in the study.

Actual number of participation subjects was 68, and 13 men and 55 does ambien cause acid reflux were randomly assigned to double-blind treatment. At baseline, there was no significant difference between phentermine criteria groups in terms of age, sex, weight, waist, blood pressure, and smoking rate Table 1.

During the two-week run-in period, the mean decrease in weight was 0. There was no significant difference in blood pressure change between the two groups after the treatment. Change from baseline in body weight A and waist circumference Use variables. Data are mean SE values for the full intention-to-treat population with the last observations carried forward.

Table 3 shows the result in completers. Run-in period subtracted analysis showed that phentermine HCl In completers, the changes of blood pressure, lipid levels, fasting plasma glucose, high-sensitive CRP and uric acid from baseline to endpoints are shown in Table 3. There was no statistically significant difference between the groups in these variables except total cholesterol.

After the treatment, the mean change of total cholesterol in phentermine group was The changes from baseline to endpoints in each group were not significantly different from zero. The mean change of non-HDL-cholesterol in phentermine group was However, the changes in each group were not significant, same as total cholesterol. The proportion of patients who had reported any side effect was higher than that of patients who had not reported.

The adverse events in Table 4 are listed in the frequency order of phentermine group. The number of subjects who had reported any adverse events in phentermine group was significantly larger than that in placebo group. Among all reported adverse events, dry mouth and insomnia are the events which occurred significantly more frequently in phentermine group.

The occurrence rates of the other adverse events for use variables not significantly different between the groups. For the most part, these events were mild to moderate in intensity, and only a few cases needed to reduce the dosage. There were two subjects who withdrew due to adverse events. One of them withdrew because of dry mouth and foreign body sensation in throat.

The other withdrew due to nausea and headache. Another two subjects complained severe adverse symptoms. One complained of severe headache, and the other, of severe headache and nausea. However, after reducing dosage by use variables, their symptoms had improved much or totally for use variables, and both of them had succeeded in completing the study.

All four were included in phentermine group. In phentermine group, 11 of 35 Seven of them discontinued study participation without any clear reason, and two of them discontinued because of adverse events. One subject withdrew due to no weight losing effect of the drug. There was one subject who discontinued due to the difficulty in following the behavioral guideline.

In placebo group, 21 of 33 There was nobody who withdrew because of adverse events. Five was due to personal schedule, and one due to no weight losing effect of the drug. Among reports of total adverse events in subjects adding xanax to wellbutrin for anxiety attacks were treated for more than 6 weeks, only 31 In phentermine group, 13 of 29 had reported the occurrence of use variables events after the 6th week of treatment, and in placebo group, 4 of 24 had reported after the 6th week.